Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer

Background: Biomarkers for metastatic castration-resistant prostatic cancer (mCRPC) are an unmet medical need. Methods: The prognostic and predictive value for survival and response to salvage hormonal therapy (SHT) of baseline testosterone level (TL) was analysed in a cohort of 101 mCRPC patients p...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2014-04, Vol.110 (9), p.2201-2208
Main Authors: de Liaño, A G, Reig, O, Mellado, B, Martin, C, Rull, E U, Maroto, J P
Format: Article
Language:English
Subjects:
692/53/2422
692/699/67/1059/99
692/699/67/589/466
Aged
Aged, 80 and over
Anemia
Antigens
Biological and medical sciences
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Chemotherapy
Clinical Study
Drug Resistance
Endocrine therapy
Epidemiology
Humans
Immunoassay
Male
Medical sciences
Metastasis
Middle Aged
Molecular Medicine
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasm Metastasis
Nephrology. Urinary tract diseases
Oncology
Plasma
Predictive Value of Tests
Prognosis
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - blood
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Testosterone
Testosterone - blood
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Biomarkers for metastatic castration-resistant prostatic cancer (mCRPC) are an unmet medical need. Methods: The prognostic and predictive value for survival and response to salvage hormonal therapy (SHT) of baseline testosterone level (TL) was analysed in a cohort of 101 mCRPC patients participating in 9 non-hormonal first-line chemotherapy phase II–III trials. Inclusion criteria in all trials required a TL of
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2014.189